This is the authors' abstract. We don't add key points for this paper.
Information that has accumulated in the past several years has necessitated a radical reexamination of the role of complement in immune-complex disease. The starting point was the recognition in the mid-1970s of an association between a genetic deficiency of complement components and susceptibility to immune-complex disease. More recent work has established that complement itself, by binding to the antigen–antibody complex, can greatly modify the structure and biologic activity of the complex. In addition, the structure and properties of the receptor for the activated third component of complement have been characterized. These new data have led to a reappraisal of the . . .
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Epstein et al. (1986) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: